TY - JOUR
T1 - Younger children develop higher effector antibody responses to SARS-CoV-2 infection
AU - Tomasi, Lisa
AU - Thiriard, Anais
AU - Heyndrickx, Leo
AU - Georges, Daphnée
AU - Van den Wijngaert, Sigi
AU - Olislagers, Véronique
AU - Sharma, Shilpee
AU - Matagne, André
AU - Ackerman, Margaret E
AU - Ariën, Kevin K
AU - Goetghebuer, Tessa
AU - Marchant, Arnaud
N1 - FTX; DOAJ; (CC BY-NC-ND 4.0)
PY - 2022
Y1 - 2022
N2 - BACKGROUND: The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect children.METHODS: To test this hypothesis, we conducted a detailed analysis of antibodies induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children aged 2 months to 14 years.RESULTS: Younger children had higher titers of antibodies to SARS-CoV-2 receptor binding domain (RBD), S1 but not S2 domain, and total spike (S) protein, higher avidity RBD immunoglobulin G, and higher titers of neutralizing and complement-activating antibodies as compared with older children. In contrast, older children had higher titers of antibodies to HCoVs, which correlated with antibodies to the SARS-CoV-2 S2 domain but not with neutralizing or complement-activating antibodies.CONCLUSIONS: These results reveal a unique capacity of young children to develop effector antibody responses to SARS-CoV-2 infection independently of their immunity to HCoVs.
AB - BACKGROUND: The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect children.METHODS: To test this hypothesis, we conducted a detailed analysis of antibodies induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children aged 2 months to 14 years.RESULTS: Younger children had higher titers of antibodies to SARS-CoV-2 receptor binding domain (RBD), S1 but not S2 domain, and total spike (S) protein, higher avidity RBD immunoglobulin G, and higher titers of neutralizing and complement-activating antibodies as compared with older children. In contrast, older children had higher titers of antibodies to HCoVs, which correlated with antibodies to the SARS-CoV-2 S2 domain but not with neutralizing or complement-activating antibodies.CONCLUSIONS: These results reveal a unique capacity of young children to develop effector antibody responses to SARS-CoV-2 infection independently of their immunity to HCoVs.
U2 - 10.1093/ofid/ofac554
DO - 10.1093/ofid/ofac554
M3 - A1: Web of Science-article
C2 - 36467295
SN - 2328-8957
VL - 9
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
IS - 11
M1 - ofac554
ER -